Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-019762
Filing Date
2021-05-18
Accepted
2021-05-18 16:45:25
Documents
1
Period of Report
2021-05-14

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3169
  Complete submission text file 0000899243-21-019762.txt   4669
Mailing Address C/O SUCAMPO PHARMACEUTICALS 805 KING FARM BOULEVARD, SUITE 550 ROCKVILLE MD 20850
Business Address
Meyenburg Jason Patrick (Reporting) CIK: 0001709008 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39438 | Film No.: 21936729

Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Issuer) CIK: 0001816736 (see all company filings)

EIN.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations